

Supplementary Table 2: Prevalence of remission and LDA in the several cohorts as a function of the different definitions.*

Authors	Country/Region	Year of publication	Patients	Ethnicity					Cross-sectional or longitudinal	Follow-up years	Remission						% on remission	
				Caucasian	Asian	Mestizo/Hispanic	African descendant	Others			Disease activity index	Immunological activity	PGA	Prednisone daily dose	Immunosuppressive drug use	Antimalarial use	Minimal duration	
Drenkard	Mexico	1996	667	NR	NR	NR	NR	NR	Longitudinal	11.6	Lack of clinical disease activity (no formal index was used)	Allowed	NR	Not allowed	Not allowed	Not allowed	1 year	23.4
Medina-Quiñones	UK	2016	532	55.3	4.1+13.9 (Indian)	NR	10.9	6.8	Longitudinal	12	BILAG C, D, E	Allowed	NR	0	Not allowed	Allowed	3 years	22.9
Medina-Quiñones	UK	2016	532	55.3	4.1+13.9 (Indian)	NR	10.9	6.8	Longitudinal	12	BILAG C, D, E	Not allowed	NR	0	Not allowed	Allowed	3 years	14.5
Polachek	Canada	2017	620	NR	NR	NR	NR	NR	Longitudinal	4	SLEDAI=0	Not allowed	NR	Not allowed	Not allowed	Allowed	1 year	30.8
Zen	Italy	2017	293	100	0	0	0	0	Longitudinal	7	Clinical SLEDAI=0	Allowed	NR	≤5	Allowed	Allowed	1 year	88.1
Zen	Italy	2017	293	100	0	0	0	0	Longitudinal	7	Clinical SLEDAI=0	Allowed	NR	≤5	Allowed	Allowed	2 year	78.8
Zen	Italy	2017	293	100	0	0	0	0	Longitudinal	7	Clinical SLEDAI=0	Allowed	NR	≤5	Allowed	Allowed	3 year	62.8
Zen	Italy	2017	293	100	0	0	0	0	Longitudinal	7	Clinical SLEDAI=0	Allowed	NR	≤5	Allowed	Allowed	4 year	47.4
Zen	Italy	2017	293	100	0	0	0	0	Longitudinal	7	Clinical SLEDAI=0	Allowed	NR	≤5	Allowed	Allowed	5 year	38.6
Ugarte-Gil	Latin America	2017	1350	41.8	NR	42.7	11.7	3.8	Longitudinal	2.4	SLEDAI=0	Not allowed	NR	≤5	Allowed	Allowed	at least once	20.2
Tsang-A-Sjoe	Netherlands	2017	183	68.3	NR	NR	NR	31.7	Longitudinal	5	Clinical SLEDAI=0	Allowed	NR	≤5	Allowed	Allowed	1 year	54.6
Tsang-A-Sjoe	Netherlands	2017	183	68.3	NR	NR	NR	31.7	Longitudinal	5	Clinical SLEDAI=0	Allowed	NR	≤5	Allowed	Allowed	2 years	43.8
Tsang-A-Sjoe	Netherlands	2017	183	68.3	NR	NR	NR	31.7	Longitudinal	5	Clinical SLEDAI=0	Allowed	NR	≤5	Allowed	Allowed	3 years	39.6
Tsang-A-Sjoe	Netherlands	2017	183	68.3	NR	NR	NR	31.7	Longitudinal	5	Clinical SLEDAI=0	Allowed	NR	≤5	Allowed	Allowed	4 years	33.0
Tsang-A-Sjoe	Netherlands	2017	183	68.3	NR	NR	NR	31.7	Longitudinal	5	Clinical SLEDAI=0	Allowed	NR	≤5	Allowed	Allowed	5 years	32.5
Mok	Hong Kong	2017	769	0	100	0	0	0	Longitudinal	≥5	Clinical SLEDAI=0	Allowed	<0.5	≤5	Allowed	Allowed	1 year	60.1
Mok	Hong Kong	2017	769	0	100	0	0	0	Longitudinal	≥5	Clinical SLEDAI=0	Allowed	<0.5	≤5	Allowed	Allowed	3 years	43.0
Mok	Hong Kong	2017	769	0	100	0	0	0	Longitudinal	≥5	Clinical SLEDAI=0	Allowed	<0.5	≤5	Allowed	Allowed	5 years	31.5
Mok	Hong Kong	2017	769	0	100	0	0	0	Longitudinal	≥5	Clinical SLEDAI=0	Allowed	<0.5	≤5	Allowed	Allowed	7 years	24.9
Mok	Hong Kong	2017	769	0	100	0	0	0	Longitudinal	≥5	Clinical SLEDAI=0	Allowed	<0.5	0	Not allowed	Allowed	1 year	18.6
Mok	Hong Kong	2017	769	0	100	0	0	0	Longitudinal	≥5	Clinical SLEDAI=0	Allowed	<0.5	0	Not allowed	Allowed	3 years	16.8
Mok	Hong Kong	2017	769	0	100	0	0	0	Longitudinal	≥5	Clinical SLEDAI=0	Allowed	<0.5	0	Not allowed	Allowed	5 years	14.4
Mok	Hong Kong	2017	769	0	100	0	0	0	Longitudinal	≥5	Clinical SLEDAI=0	Allowed	<0.5	0	Not allowed	Allowed	7 years	13.9
Mok	Hong Kong	2017	769	0	100	0	0	0	Longitudinal	≥5	Clinical SLEDAI=0	Not allowed	<0.5	≤5	Allowed	Allowed	1 year	33.2
Mok	Hong Kong	2017	769	0	100	0	0	0	Longitudinal	≥5	Clinical SLEDAI=0	Not allowed	<0.5	≤5	Allowed	Allowed	3 years	26.2
Mok	Hong Kong	2017	769	0	100	0	0	0	Longitudinal	≥5	Clinical SLEDAI=0	Not allowed	<0.5	≤5	Allowed	Allowed	5 years	21.0
Mok	Hong Kong	2017	769	0	100	0	0	0	Longitudinal	≥5	Clinical SLEDAI=0	Not allowed	<0.5	≤5	Allowed	Allowed	7 years	17.4
Mok	Hong Kong	2017	769	0	100	0	0	0	Longitudinal	≥5	Clinical SLEDAI=0	Not allowed	<0.5	0	Not allowed	Allowed	1 year	13.3

Mok	Hong Kong	2017	769	0	100	0	0	0	Longitudinal	≥5	Clinical SLEDAI=0	Not allowed	<0.5	0	Not allowed	Allowed	3 years	12.4	
Mok	Hong Kong	2017	769	0	100	0	0	0	Longitudinal	≥5	Clinical SLEDAI=0	Not allowed	<0.5	0	Not allowed	Allowed	5 years	10.9	
Mok	Hong Kong	2017	769	0	100	0	0	0	Longitudinal	≥5	Clinical SLEDAI=0	Not allowed	<0.5	0	Not allowed	Allowed	7 years	10.4	
Petri	US	2018	1356	55	NR	NR	38	7	Longitudinal	3.8	Clinical SLEDAI=0	Allowed	<0.5	≤5	Allowed	Allowed	NR	NR	
Petri	US	2018	1356	55	NR	NR	38	7	Longitudinal	3.8	Clinical SLEDAI=0	Allowed	<0.5	0	Allowed	Allowed	NR	NR	
Tani	Italy	2018	115	NR	NR	NR	NR	NR	Longitudinal	≥5	Clinical SLEDAI=0	Allowed	<0.5	≤5	Allowed	Allowed	100% of the follow-up	21.7	
Poomsalood	Thailand	2018	237	NR	NR	NR	NR	NR	cross-sectional	NR	Clinical SLEDAI=0	Allowed	NR	≤5	Allowed	Allowed	1 year	42.2	
Alarcon	US	2019	558	28	0	35	37	0	Longitudinal	NR	SLAM=0	NR	NR	5	Not allowed	Allowed	NR	NR	
Mathian A	France	2019	407	NR	NR	NR	NR	NR	Longitudinal	1	SLEDAI=0	Not allowed	NR	0	Allowed	Allowed	NR	21.1	
Mathian A	France	2019	407	NR	NR	NR	NR	NR	Longitudinal	1	SLEDAI=0	Not allowed	NR	≤5	Not allowed	Allowed	NR	35.6	
Mathian A	France	2019	407	NR	NR	NR	NR	NR	Longitudinal	1	Clinical SLEDAI=0	Allowed	NR	0	Allowed	Allowed	NR	32.6	
Mathian A	France	2019	407	NR	NR	NR	NR	NR	Longitudinal	1	Clinical SLEDAI=0	Allowed	NR	≤5	Not allowed	Allowed	NR	62.4	
Golder	Asia Pacific	2019	1707	10.1	87.7	0	0	2.2	longitudinal	2.2	Clinical SLEDAI=0	Allowed	<0.5	0	Allowed	Allowed	NR	24.8	
Golder	Asia Pacific	2019	1707	10.1	87.7	0	0	2.2	longitudinal	2.2	Clinical SLEDAI=0	Allowed	<0.5	0	Not allowed	Allowed	NR	18.4	
Golder	Asia Pacific	2019	1707	10.1	87.7	0	0	2.2	longitudinal	2.2	Clinical SLEDAI=0	Allowed	<0.5	≤5	Allowed	Allowed	NR	60.9	
Golder	Asia Pacific	2019	1707	10.1	87.7	0	0	2.2	longitudinal	2.2	Clinical SLEDAI=0	Allowed	<0.5	≤5	Not allowed	Allowed	NR	38.2	
Golder	Asia Pacific	2019	1707	10.1	87.7	0	0	2.2	longitudinal	2.2	Clinical SLEDAI=0	Not allowed	<0.5	0	Allowed	Allowed	NR	14.4	
Golder	Asia Pacific	2019	1707	10.1	87.7	0	0	2.2	longitudinal	2.2	Clinical SLEDAI=0	Not allowed	<0.5	0	Not allowed	Allowed	NR	11.1	
Golder	Asia Pacific	2019	1707	10.1	87.7	0	0	2.2	longitudinal	2.2	Clinical SLEDAI=0	Not allowed	<0.5	≤5	Allowed	Allowed	NR	34.4	
Golder	Asia Pacific	2019	1707	10.1	87.7	0	0	2.2	longitudinal	2.2	Clinical SLEDAI=0	Not allowed	<0.5	≤5	Not allowed	Allowed	NR	21.4	
Ugarte-Gil	US	2019	483	NR	NR	NR	NR	0	Longitudinal	NR	SLAM=0	NR	NR	5	Not allowed	Allowed	NR	NR	
Reatetgui-Sokolova	Peru	2019	315	NR	NR	NR	NR	NR	longitudinal	NR	SLEDAI=0	Not allowed	NR	≤5	Allowed	Allowed	NR	11.7 at baseline	
Margiotta	Italy	2019	136	NR	NR	NR	NR	NR	cross-sectional	NR	Clinical SLEDAI=0	Allowed	NR	≤5	Allowed	Allowed	NR	82 at least one year	
Fasano	Italy	2019	294	NR	NR	NR	NR	NR	Longitudinal	9	Clinical SLEDAI=0	Allowed	NR	≤5	Allowed	Allowed	5	44.5	
Goswani	India	2019	126	NR	NR	NR	NR	NR	Longitudinal	0.5	Clinical SLEDAI=0	Allowed	<0.5	Allowed	allowed	Allowed	NR	NR	
Goswani	India	2019	126	NR	NR	NR	NR	NR	Longitudinal	0.5	Clinical SLEDAI=0	Not allowed	<0.5	Allowed	allowed	Allowed	NR	NR	
Tsang-A-Sjoe	Netherlands	2019	154	69.5%	NR	NR	NR	30.5%	Longitudinal	2	Clinical SLEDAI=0	Allowed	≤2/10	≤5	Allowed	Allowed	NR	At baseline 39.0	
Tsang-A-Sjoe	Netherlands	2019	154	69.5%	NR	NR	NR	30.5%	Longitudinal	2	Clinical SLEDAI=0	Allowed	≤2/10	not allowed	not allowed	Allowed	NR	At baseline 24.0	
Floris	Italy	2020	116	100%	0	0	0	0	Longitudinal	1.5	Clinical SLEDAI=0	allowed	<0.5	Allowed	allowed	Allowed	NR	21.6 at 6 months	
Floris	Italy	2020	116	100%	0	0	0	0	Longitudinal	1.5	Clinical SLEDAI=0	allowed	<0.5	Allowed	allowed	Allowed	NR	31.9 at 18 months	
Ugarte-Gil	Peru	2020	208	NR	NR	NR	NR	NR	longitudinal	2.2	SLEDAI=0	Not allowed	NR	≤5	Allowed	Allowed	NR	NR	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	Any	Allowed	Any	≤5	Allowed	Allowed	1 year	88.7	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	Any	Allowed	Any	≤5	Allowed	Allowed	2 years	79.3	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	Any	Allowed	Any	≤5	Allowed	Allowed	3 years	65.8	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	Any	Allowed	Any	≤5	Allowed	Allowed	4 years	53.4	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	Any	Allowed	Any	≤5	Allowed	Allowed	5 years	34.4	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	Any	Allowed	<0.5	Allowed	Allowed	Allowed	1 year	74.6	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	Any	Allowed	<0.5	Allowed	Allowed	Allowed	2 years	58.4	

Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	Any	Allowed	<0.5	Allowed	Allowed	Allowed	3 years	40.9	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	Any	Allowed	<0.5	Allowed	Allowed	Allowed	4 years	26.8	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	Any	Allowed	<0.5	Allowed	Allowed	Allowed	5 years	13.0	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	CSLEAI=0	Allowed	Any	Allowed	Allowed	Allowed	1 year	84.8	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	CSLEAI=0	Allowed	Any	Allowed	Allowed	Allowed	2 years	70.6	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	CSLEAI=0	Allowed	Any	Allowed	Allowed	Allowed	3 years	50.6	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	CSLEAI=0	Allowed	Any	Allowed	Allowed	Allowed	4 years	38.7	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	CSLEAI=0	Allowed	Any	Allowed	Allowed	Allowed	5 years	18.4	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	Any	Allowed	<0.5	<=5	Allowed	Allowed	1 year	70.0	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	Any	Allowed	<0.5	<=5	Allowed	Allowed	2 years	54.5	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	Any	Allowed	<0.5	<=5	Allowed	Allowed	3 years	38.4	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	Any	Allowed	<0.5	<=5	Allowed	Allowed	4 years	25.7	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	Any	Allowed	<0.5	<=5	Allowed	Allowed	5 years	12.5	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	CSLEAI=0	Allowed	<0.5	Allowed	Allowed	Allowed	1 year	73.7	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	CSLEAI=0	Allowed	<0.5	Allowed	Allowed	Allowed	2 years	57.1	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	CSLEAI=0	Allowed	<0.5	Allowed	Allowed	Allowed	3 years	39.3	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	CSLEAI=0	Allowed	<0.5	Allowed	Allowed	Allowed	4 years	25.9	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	CSLEAI=0	Allowed	<0.5	Allowed	Allowed	Allowed	5 years	12.7	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	CSLEAI=0	Allowed	Any	<=5	Allowed	Allowed	1 year	77.2	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	CSLEAI=0	Allowed	Any	<=5	Allowed	Allowed	2 years	63.2	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	CSLEAI=0	Allowed	Any	<=5	Allowed	Allowed	3 years	45.5	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	CSLEAI=0	Allowed	Any	<=5	Allowed	Allowed	4 years	34.1	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	CSLEAI=0	Allowed	Any	<=5	Allowed	Allowed	5 years	16.6	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	CSLEAI=0	Allowed	<0.5	<=5	Allowed	Allowed	1 year	69.2	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	CSLEAI=0	Allowed	<0.5	<=5	Allowed	Allowed	2 years	53.6	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	CSLEAI=0	Allowed	<0.5	<=5	Allowed	Allowed	3 years	37.6	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	CSLEAI=0	Allowed	<0.5	<=5	Allowed	Allowed	4 years	24.9	
Saccon	Italy	2020	646	NR	NR	NR	NR	NR	Longitudinal	5	CSLEAI=0	Allowed	<0.5	<=5	Allowed	Allowed	5 years	12.4	
Jakez-Ocampo	Mexico	2020	NR (case control)	NR	NR	NR	NR	NR	Cross-sectional	NR	CSLEAI=0	Allowed	NR	0	Not allowed	Not allowed	10 years	NR	
Nikfar	Iran	2020	193	NR	NR	NR	NR	NR	Longitudinal	8	CSLEAI=0	Allowed	<0.5	<=5	Not allowed	Allowed	1 year	49.2	
Nikfar	Iran	2020	193	NR	NR	NR	NR	NR	Longitudinal	8	CSLEAI=0	Allowed	<0.5	<=5	Not allowed	Allowed	5 years	24.4	
Nikfar	Iran	2020	193	NR	NR	NR	NR	NR	Longitudinal	8	CSLEAI=0	Allowed	<0.5	0	Not allowed	Allowed	1 year	38.9	
Nikfar	Iran	2020	193	NR	NR	NR	NR	NR	Longitudinal	8	CSLEAI=0	Allowed	<0.5	0	Not allowed	Allowed	5 years	35.2	
Nikfar	Iran	2020	193	NR	NR	NR	NR	NR	Longitudinal	8	CSLEAI=0	Not allowed	<0.5	0	Not allowed	Allowed	1 year	19.2	
Nikfar	Iran	2020	193	NR	NR	NR	NR	NR	Longitudinal	8	CSLEAI=0	Not allowed	<0.5	0	Not allowed	Allowed	5 years	13.5	
Authors	Country/Region	Year of publication	Patients	Ethnicity					Cross-sectional or longitudinal	Follow-up years	LDA								% on LDA
				Caucasian	Asian	Mestizo/Hispanic	African descendant	Others			Disease activity index	Exclusion of New activity	Major Organ Exclusion	PGA	Prednisone daily dose	Immunosuppressive drug use	Antimalarial use	Minimal duration	
Polachek	Canada	2017	620	NR	NR	NR	NR	NR	Longitudinal	4	SLEDAI<=2	No	No	NR	Not allowed	Not allowed	Allowed	1 year	43.7
Ugarte-Gil	Latin America	2017	1350	41.8		42.7	11.7	3.8	Longitudinal	2.4	SLEDAI<=4	No	No	NR	<=7.5	Allowed	Allowed	at least once	34.4
Tsang-A-Sjoe	Netherlands	2017	183	68.3	NR	NR	NR	31.7	Longitudinal	5	SLEDAI<=4	No	Yes	<=2/10	<=7.5	Allowed	Allowed	1 year	56.2
Golder	Asia Pacific	2017	1422	8	90	NR	NR	2	cross-sectional	NR	SLEDAI<=4	Yes	Yes	<=1	<=7.5	Allowed	Allowed	NR	42
Tani	Italy	2018	115	NR	NR	NR	NR	NR	Longitudinal	at least 5	SLEDAI<=4	No	Yes	<=1	<=7.5	Allowed	Allowed	100% of the follow-up	36.5
Tani	Italy	2018	115	NR	NR	NR	NR	NR	Longitudinal	at least 5	SLEDAI<=4	No	Yes	<=1	<=7.5	Allowed	Allowed	50%	70.4
Zen	Italy	2018	293	100	0	0	0	0	Longitudinal	7	SLEDAI<=4	Yes	Yes	<=1	<=7.5	Allowed	Allowed	1 year	87.0
Zen	Italy	2018	293	100	0	0	0	0	Longitudinal	7	SLEDAI<=4	Yes	Yes	<=1	<=7.5	Allowed	Allowed	2 year	75.8
Zen	Italy	2018	293	100	0	0	0	0	Longitudinal	7	SLEDAI<=4	Yes	Yes	<=1	<=7.5	Allowed	Allowed	3 year	61.1
Zen	Italy	2018	293	100	0	0	0	0	Longitudinal	7	SLEDAI<=4	Yes	Yes	<=1	<=7.5	Allowed	Allowed	4 year	47.8
Zen	Italy	2018	293	100	0	0	0	0	Longitudinal	7	SLEDAI<=4	Yes	Yes	<=1	<=7.5	Allowed	Allowed	5 year	37.2
Petri	US	2018	1356	55	NR	NR	38	7	Longitudinal	NR	SLEDAI<=4	Yes	Yes	<=1	<=7.5	Allowed	Allowed	NR	NR
Poomsalood	Thailand	2018	237	NR	NR	NR	NR	NR	cross-sectional	NR	C-SLEDAI<=2	No	No	NR	<=7.5	Allowed	Allowed	1 year	6.16
Alarcon	US	2019	558	28	0	35	37	0	Longitudinal	NR	SLAM<=3	No	No	NR	<=7.5	Not allowed	Allowed	NR	NR

Mathian A	France	2019	407	NR	NR	NR	NR	NR	Longitudinal	1	SLEDAI<=4	Yes	Yes	NR	<=7.5	Allowed	Allowed	NR	12.4 (excluding remission)
Golder	Asia Pacific	2019	1707	10.1	87.7	0	0	2.2	longitudinal	2.2	SLEDAI<=4	Yes	Yes	<=1	<=7.5	Allowed	Allowed	50%	47.0
Golder	Asia Pacific	2019	1707	10.1	87.7	0	0	2.2	longitudinal	2.2	SLEDAI<=4	Yes	Yes	<=1	<=7.5	Allowed	Allowed	At least once	78.0
Golder	Asia Pacific	2019	1707	10.1	87.7	0	0	2.2	longitudinal	2.2	SLEDAI<=4	Yes	Yes	<=1	<=7.5	Allowed	Allowed	at least 12 months	48.2
Ugarte-Gil	USA	2019	483	NR	NR	NR	NR	NR	Longitudinal	NR	SLAM<=3	No	No	NR	<=7.5	Not allowed	Allowed	NR	NR
Reatetgui-Sokolova	Peru	2019	315	NR	NR	NR	NR	NR	longitudinal	NR	SLEDAI<=4	No	No	NR	<=7.5	Allowed	Allowed	at least once	30,5 at baseline
Ugarte-Gil	Peru	2019	208	NR	NR	NR	NR	NR	longitudinal	2.2	SLEDAI<=4	No	No	NR	<=7.5	Allowed	Allowed	at least once	61.6% of the visits
Sharma	Norway	2020	206	100	0	0	0	0	longitudinal	10	SLEDAI<=4	Yes	Yes	NR	<=7.5	Allowed	Allowed	30%	55.3
Sharma	Norway	2020	206	100	0	0	0	0	longitudinal	10	SLEDAI<=4	Yes	Yes	NR	<=7.5	Allowed	Allowed	50%	33.5
Sharma	Norway	2020	206	100	0	0	0	0	longitudinal	10	SLEDAI<=4	Yes	Yes	NR	<=7.5	Allowed	Allowed	70%	18.4
Yeo	Australia	2020	200	52	39.5	NR	NR	8.5	longitudinal	2.1	SLEDAI<=4	Yes	Yes	<=1	<=7.5	Allowed	Allowed	50%	51
Floris	Italy	2020	116	100%	0	0	0	0	Longitudinal	1.5	SLEDAI<=4	Yes	Yes	<=1	<=7.5	Allowed	Allowed	NR	42.2 at 6 months
Floris	Italy	2020	116	100%	0	0	0	0	Longitudinal	1.5	SLEDAI<=4	Yes	Yes	<=1	<=7.5	Allowed	Allowed	NR	46.2 at 18 months
Loothrenoo	Thailand	2020	337	NR	NR	NR	NR	NR	Longitudinal	3.2	SLEDAI<=4	Yes	Yes	<=1	<=7.5	Allowed	Allowed	NR	80.7
Kang	Korea	2020	299	NR	NR	NR	NR	NR	Longitudinal	4	Clinical SLEDAI<=1	NR	NR	NR	5	Allowed	Allowed	NR	29.1 (year 1)
Kang	Korea	2020	299	NR	NR	NR	NR	NR	Longitudinal	4	Clinical SLEDAI<=2	NR	NR	NR	0	Not allowed	allowed	NR	4.0 (year 1)
Kang	Korea	2020	299	NR	NR	NR	NR	NR	Longitudinal	4	SLEDAI<=4	Yes	Yes	<=1	<=7.5	Allowed	Allowed	NR	70.2 (year 1)

LDA: Low disease activity. PGA: Physician Global Assessment. NR: Not reported. LDA: Low Disease Activity. *If an article included more than one definition, a row per definition is included.